Trending...
- READY FOR NEW BUILDS – Pond & Waterfall Construction Season Starts Now!
- Generic Trade Marks 15 Years of Leveling the Trading Field for all Futures Traders
- Levata Acquires Logiscenter to Accelerate Growth in Enterprise IT and Data Capture Solutions
CHICAGO, June 23, 2025 ~ New studies have revealed promising results for two medications, orfoglipron and MariTide, in the treatment of type 2 diabetes and obesity. The findings from the ACHIEVE-1 Trial and the MariTide Phase 2 Trial were simultaneously published in the New England Journal of Medicine (NEJM) and presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago.
According to recent statistics, more than 2 in 5 adults in the US are obese or severely obese, while an estimated 90 to 95% of over 38 million Americans with diabetes have type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists are a well-established treatment option for both conditions. However, there is a growing need for additional options that cater to patient preferences and provide tailored care, such as oral forms or injectables with less frequent dosing.
The MariTide Phase 2 Trial, which enrolled 592 adults, demonstrated weight loss and A1C reduction in both groups with and without type 2 diabetes. This trial evaluated MariTide, a novel long-acting GLP-1 receptor agonist and GIP receptor antagonist. Participants were assigned to different monthly fixed dose regimens or an every-8-week dose regimen. The results showed an average weight loss of up to approximately 20% in participants with obesity alone and a weight loss and A1C reduction of up to approximately 17% and 2.2%, respectively, in those with obesity and type two diabetes. Additionally, there were improvements in other cardiometabolic measures such as blood pressure and lipid levels. These positive outcomes suggest that MariTide has the potential to be a once-monthly treatment option for both conditions.
More on illi News
Dr. Ania M. Jastreboff, professor at Yale School of Medicine (Endocrinology) and director of the Y-Weight Yale Obesity Research Center, expressed her excitement about the potential of MariTide as a once-monthly treatment option for people with obesity. She stated, "Once-monthly treatment options for type 2 diabetes have long been sought after, yet elusive. MariTide has the potential to be a once-monthly treatment option for people with obesity, with and without type 2 diabetes, resulting in substantial weight reduction and robust improvements in glycemia."
The study also revealed that more than 90% of eligible participants have enrolled for an additional 52 weeks of the study (Part 2). This second part will evaluate the impact of MariTide on sustained weight loss with lower doses, less frequent dosing, or discontinuation and is expected to conclude later this year.
In another breakthrough study, the ACHIEVE-1 Trial demonstrated the safety and effectiveness of orfoglipron, the first oral small molecule non-peptide GLP-1 RA to successfully complete a Phase 3 trial. The trial enrolled 559 patients with type 2 diabetes who were not taking any glucose-lowering medications and had inadequate glycemic control across multiple countries. The results showed that orfoglipron significantly lowered A1C levels by an average rate of 1.3% to 1.6% across doses from a baseline of 8.0%. Additionally, participants experienced an average weight loss of 7.9% (roughly 16lbs) at the highest dose, with indications of further potential weight loss as they did not reach a plateau at the end of the study.
More on illi News
One significant advantage of orfoglipron is that it can be taken as a once-daily pill without any food or water restrictions. This contributed to approximately 73% of participants in the treatment regimen achieving their A1C target, with a potential increase up to 76%.
These groundbreaking studies provide hope for individuals with type 2 diabetes and obesity, as they offer new treatment options that can potentially lead to significant weight loss and improved glycemic control. The results of these trials have been published in prestigious medical journals and presented at a major scientific conference, highlighting their significance in the field of diabetes and obesity research.
According to recent statistics, more than 2 in 5 adults in the US are obese or severely obese, while an estimated 90 to 95% of over 38 million Americans with diabetes have type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists are a well-established treatment option for both conditions. However, there is a growing need for additional options that cater to patient preferences and provide tailored care, such as oral forms or injectables with less frequent dosing.
The MariTide Phase 2 Trial, which enrolled 592 adults, demonstrated weight loss and A1C reduction in both groups with and without type 2 diabetes. This trial evaluated MariTide, a novel long-acting GLP-1 receptor agonist and GIP receptor antagonist. Participants were assigned to different monthly fixed dose regimens or an every-8-week dose regimen. The results showed an average weight loss of up to approximately 20% in participants with obesity alone and a weight loss and A1C reduction of up to approximately 17% and 2.2%, respectively, in those with obesity and type two diabetes. Additionally, there were improvements in other cardiometabolic measures such as blood pressure and lipid levels. These positive outcomes suggest that MariTide has the potential to be a once-monthly treatment option for both conditions.
More on illi News
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
- Chicago: Mayor Johnson, City Officials Honor 1995 Heat Wave Victims, Forgotten WWII Hero Emilio Aguirre with Full Military Funeral Honors
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- Disposable Vape Ban Spurs Hayati Innovation
- Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work
Dr. Ania M. Jastreboff, professor at Yale School of Medicine (Endocrinology) and director of the Y-Weight Yale Obesity Research Center, expressed her excitement about the potential of MariTide as a once-monthly treatment option for people with obesity. She stated, "Once-monthly treatment options for type 2 diabetes have long been sought after, yet elusive. MariTide has the potential to be a once-monthly treatment option for people with obesity, with and without type 2 diabetes, resulting in substantial weight reduction and robust improvements in glycemia."
The study also revealed that more than 90% of eligible participants have enrolled for an additional 52 weeks of the study (Part 2). This second part will evaluate the impact of MariTide on sustained weight loss with lower doses, less frequent dosing, or discontinuation and is expected to conclude later this year.
In another breakthrough study, the ACHIEVE-1 Trial demonstrated the safety and effectiveness of orfoglipron, the first oral small molecule non-peptide GLP-1 RA to successfully complete a Phase 3 trial. The trial enrolled 559 patients with type 2 diabetes who were not taking any glucose-lowering medications and had inadequate glycemic control across multiple countries. The results showed that orfoglipron significantly lowered A1C levels by an average rate of 1.3% to 1.6% across doses from a baseline of 8.0%. Additionally, participants experienced an average weight loss of 7.9% (roughly 16lbs) at the highest dose, with indications of further potential weight loss as they did not reach a plateau at the end of the study.
More on illi News
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Samyang Corporation Unveils 'AI-Based Standardized Sugar Reduction Solution' at US Food Technology Expo
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
One significant advantage of orfoglipron is that it can be taken as a once-daily pill without any food or water restrictions. This contributed to approximately 73% of participants in the treatment regimen achieving their A1C target, with a potential increase up to 76%.
These groundbreaking studies provide hope for individuals with type 2 diabetes and obesity, as they offer new treatment options that can potentially lead to significant weight loss and improved glycemic control. The results of these trials have been published in prestigious medical journals and presented at a major scientific conference, highlighting their significance in the field of diabetes and obesity research.
Filed Under: Business
0 Comments
Latest on illi News
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- AI Maturity Emerges as Key Driver of ROI, New Protiviti Study Finds
- Premier Custom Hardwood Flooring Launches New Website to Better Serve Homeowners and Businesses in the NW Chicago Suburbs
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- WIOA-Funded Seats Still Available for Summer Product-Owner Training
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- Entyre Solutions Launches to Support Senior Living Operators
- Jungbunzlauer Launches New TayaGel® LA at IFT First 2025, strengthening its texturants portfolio USA - English USA - English USA - Français Japan - Japanese USA - Deutsch
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Eliza Nevius Reimagines a Classic with a Dark, Witty Twist in The Key to Wonderland
- Naperville Police Initiate Death Investigation
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Mayor Johnson Appoints Era Patterson As Executive Director Of The Chicago Office Of Public Safety Administration